FLASH Pre Clinical Dosimetry

最近的超高剂量率（UHDR）（>40戈伊/s）（称为FLASH放疗（RT））的放射研究表明，相对于常规剂量率放疗（几个戈伊/min），正常组织毒性显著降低（称为“FLASH效应”），同时保持相似的肿瘤反应。这可能代表了癌症治疗的一个步骤，对患者和医疗保健提供者都有显著的好处。然而，支持FLASH效应的机制仍然未知。为了充分了解这一现象并验证临床试验方法，需要进行广泛的临床前放射研究。Xstrahl开发了临床前FLASH放射治疗系统，使领先的癌症研究团队能够进行精确的FLASH研究。.两个英国中心（癌症研究所和皇后大学贝尔法斯特）购买了我们的两个第一个SARRP FLASH系统，作为最近MRC赠款（世界级实验室投资）的一部分。现在，我们必须开发一种方法来进行准确和可追溯的剂量测定，并有合适的探测器来测量在闪光制度的辐射剂量，这是在毫秒，而不是几分钟内提供。目前没有现成的剂量计可用于为临床前光子FLASH RT提供准确的剂量测量，并且FLASH放射治疗的剂量测定标准仍在形成中。癌症研究团队需要准确地知道传递到他们的样本的剂量，以便FLASH研究有效，并在英国研究小组和世界范围内复制。这对于避免临床前研究的错误解释、降低临床试验的风险以及加速临床采用FLASH治疗也至关重要。与国家物理实验室的专家团队一起，我们有机会在世界范围内的其他测量标准实验室中率先定义临床前或一般FLASH剂量学。作为一家英国制造商，这使我们走在了这项技术的最前沿。作为第一家开发并在市场上推出临床前光子FLASH系统的制造商，作为此次电话会议的一部分，将开发的剂量测定系统将是世界上第一个。这将使我们能够为更广泛的研究基础提供我们的解决方案，并有助于加速将FLASH放射治疗引入临床实践。

Recent radiation studies with ultra-high dose rates, UHDR, (\>40 Gy/s), known as FLASH radiotherapy (RT), have demonstrated a remarkable reduction in normal tissue toxicity (known as the "FLASH effect") with respect to conventional dose-rate radiotherapy (few Gy/min) while maintaining similar tumour response. This could represent a step-change in cancer treatment with significant benefits for patients and healthcare providers. However, the mechanisms underpinning the FLASH effect are still unknown. Extensive pre-clinical radiation studies are necessary to gain the full understanding of this phenomenon and validate the approach for clinical trials.Xstrahl has developed a pre-clinical FLASH radiotherapy system to enable leading cancer research teams to perform precise FLASH investigations. . Two UK centres (Institute of Cancer Research and Queens University Belfast) purchased our two first SARRP FLASH systems as part of the recent MRC grant (Investment in World Class Labs). It is now essential that we develop a methodology to carry out the accurate and traceable dosimetry and have suitable detectors to measure the radiation dose in the FLASH regime, which is delivered within milliseconds rather than minutes. No current off-the-shelf dosimeters are available to provide accurate dose measurements for pre-clinical photon FLASH RT, and the dosimetry standards for FLASH radiotherapy are still emerging. The cancer research teams need to know accurately the dose delivered to their samples for FLASH research to be valid and reproduced across the UK research groups and world-wide. This is also essential to avoid flawed interpretation of the pre-clinical studies, de-risking clinical trials and accelerate clinical adoption of FLASH treatments.With the team of experts form the National Physical Laboratory, we have the opportunity to pioneer how pre-clinical or general FLASH dosimetry is defined world-wide across other measurement standard laboratories. That puts us, as a UK manufacturer, on the forefront of this technology. As the first manufacturer to develop and introduce on the market a pre-clinical photon FLASH system, the dosimetry system to be developed as part of this call will be the world's first. This will enable us to provide our solution to a wider research base and help accelerate the introduction of FLASH radiotherapy to clinical practice.